Completed PHASE2 INTERVENTIONAL 2-arm NCT01421667

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

A Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

Sponsor: Seagen Inc.

Conditions Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin Lymphoma, T-Cell

Interventions brentuximab vedotin rituximab

Updated 8 times since 2017 Last updated: Oct 14, 2016 Started: Aug 31, 2011 Primary completion: Jun 30, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Lymphoma, B-Cell and Lymphoma, Large B-Cell, Diffuse and is currently completed. Seagen Inc. leads this study, which shows 8 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Nov 2020 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Nov 2020 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Seagen Inc.

Data source: Seagen Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Atlanta, United States , Aurora, United States , Birmingham, United States , Boston, United States , Charleston, United States , Chicago, United States , Cleveland, United States , Dallas, United States , Denver, United States and 20 more locations